Mainz Biomed NV banner

Mainz Biomed NV
F:4TO

Watchlist Manager
Mainz Biomed NV Logo
Mainz Biomed NV
F:4TO
Watchlist
Price: 8 EUR Market Closed
Market Cap: €175.1m

Mainz Biomed NV
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mainz Biomed NV
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Mainz Biomed NV
F:4TO
Research & Development
-$5.2m
CAGR 3-Years
-128%
CAGR 5-Years
-87%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Research & Development
-€2.3B
CAGR 3-Years
-35%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Research & Development
-€141.4m
CAGR 3-Years
44%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Research & Development
-€176m
CAGR 3-Years
-20%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Research & Development
-€56.9m
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Formycon AG
XETRA:FYB
Research & Development
-€15.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mainz Biomed NV
Glance View

Market Cap
175.1m EUR
Industry
Biotechnology

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 58 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

4TO Intrinsic Value
HIDDEN
Show

See Also

What is Mainz Biomed NV's Research & Development?
Research & Development
-5.2m USD

Based on the financial report for Dec 31, 2024, Mainz Biomed NV's Research & Development amounts to -5.2m USD.

What is Mainz Biomed NV's Research & Development growth rate?
Research & Development CAGR 5Y
-87%

Over the last year, the Research & Development growth was 43%. The average annual Research & Development growth rates for Mainz Biomed NV have been -128% over the past three years , -87% over the past five years .

Back to Top